

Other:

**Patient Signature** 

Dispense as written

7. Prescriber Signature

6. Patient Support Programs

**866 413-3156** toll free phone 877 834-1231 toll free fax

## Rheumatology Prescription Referral Form (A-K)

QUESTIONS? Please contact us! Send your Rx to: (optional) www.REPharmacy.com Injection training Date Medication Needed: Ship To: ( ) Patient's Home ( ) Prescriber's Office ( ) Pick-up (store location): \_ 1. Patient Information Birthdate: \_\_\_ Sex: ( ) Male ( ) Female Height: \_\_\_\_\_ Patient Name: \_\_\_ Weight: \_\_\_ Soc. Sec. #: \_\_\_\_ Preferred Phone: \_\_\_\_\_ Known Allergies: \_\_\_\_\_ City: \_ Address: \_\_\_ State: \_\_\_\_\_ Zip: \_\_ Alternate Caregiver Name: Preferred Phone: \_\_\_\_ 2. Insurance Information Please include copies of the FRONT and BACK of ALL insurance cards (prescription and medical) with this fax. 3. Prescriber Information Provider Name: \_\_\_ DEA#: \_\_\_\_\_ NPI#: \_\_\_\_ Phone: . Address: Fax: City, State, Zip: \_ Key Contact: \_\_\_ Phone: 4. Diagnosis/Clinical Information Please FAX recent clinical notes, labs, tests, with the prescription to expedite the prior authorization. BMD/T-score: \_ Date: Diagnosis: -Does patient have a latex allergy? ( ) Yes ( ) No Other: Prior failed medications (medication and duration of treatment/reason for d/c): Is Patient at risk for osteoporotic fracture as evident by any of the following? ☐ History of osteoporotic fracture Site: \_\_\_\_ Is patient currently on RA therapy? ( ) Yes ( ) No ☐ Patient has tried and failed an oral bisphosphonate Medications: \_ ☐ Patient has documented contraindication/is intolerant to oral bisphosphonate TB/PPD test given? ( ) Yes ( ) No therapy (please submit a copy of DEXA w/prescription) 5. Prescription Information | Xeljanz NOT to be used in combination with biologic DMARD's Medication Dose/Strength Qty. Refills □ 80ma/4ml ☐ 4mg/kg IV once every 4 weeks ☐ Actemra® (Tocilizumab) ☐ 200mg/10ml ☐ 400mg/20ml ☐ 162mg/0.9ml □ 400ma  $\hfill \square$  2 injections of 200mg subcutaneously, initially and at weeks 2 and 4 ☐ Cimzia® 200mg/ml Maintenance: 200mg every other week; 400mg every 4 weeks □ Enbrel® (Etanercept) □ 50mg/ml SureClick™ Autoinjector ☐ Inject 50mg subcutaneously once a week ☐ Humira® ☐ 40mg/0.8ml Pen ☐ Inject 40mg subcutaneously every other week Injection training from ☐ 40mg/0.8ml Prefilled Syringe  $\hfill \square$  Inject 40mg subcutaneously once a week My Humira □ 150mg/1.14 ☐ 200mg subcutaneously once every 2 weeks ☐ Kevzara® (Sarilumab) ☐ 200mg/1.14ml ☐ **Kineret®** (Anakinra) ☐ 100mg/0.67ml \_\_ mg/kg per day subcutaneously

By signing below, the prescriber gives consent to both, the prescription(s) above, as well as to RE Pharmacy to act as the prescriber's agent to begin and execute prior

Please sign and date below to enroll in the pharmaceutical company assisted patient support program.

Date

**Substitution Permissible** 

authorization process and to help patient apply to co-pay assistance programs, including all foundations and manufacturer assistance programs if necessary.

Date IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the intended recipient, do not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately. In no event should such material be read or retained by anyone other than the named addressee, except by express authorization of the sender to the named addressee. Pursuant to VA/OH/MO/VT law, only 1 medication is permitted per order form. Please use a new form for additional items.

# of Prescriptions:

Prescriber, please sign and date below.